- Key Insight: Discover how GLP‑1 and specialty drugs are reshaping PBM strategy and formulary design.
- What’s at Stake: Rising specialty drug costs threaten employer budgets, member access, and plan sustainability.
- Expert Quote: “We can open access and lower costs, but not both without trade‑offs,” says Mark Campbell, PharmD.
- Source: Bullets generated by AI with editorial review
As the 2026 open-enrollment season beckons, nowhere is the need for better benefits design more urgent than in the prescription drug arena — the fastest-growing portion of group health expenses for decades.
